Skip to content
Assyro AI
Back to Glossary
General

CBER(Center for Biologics Evaluation and Research)

CBER is the FDA center that licenses biological products under section 351 of the Public Health Service Act, covering vaccines, blood, allergenics, human tissues, and cell and gene therapies, rather than the therapeutic proteins CDER reviews.

Usage Examples

  • Confirm with CBER before the pre-IND meeting, because if the device is the primary mode of action this program belongs to CDRH.
  • The BLA goes to CBER, so the license decision comes from the Director of CBER and not from CDER.
  • We assumed CBER because it is a biologic, and lost six weeks finding out the antibody sits with CDER.

What is CBER (Center for Biologics Evaluation and Research)?

CBER is the FDA center that licenses biological products under section 351 of the Public Health Service Act, covering vaccines, blood, allergenics, human tissues, and cell and gene therapies, rather than the therapeutic proteins CDER reviews.

CBER exists because biological products cannot be characterized the way a small molecule can. A vaccine, a plasma derivative, or an autologous cell therapy is defined largely by the process that makes it, so the regulator licenses the establishment and the product together. Congress placed that regime in section 351 of the Public Health Service Act, and CBER administers it.

CBER covers vaccines, blood and blood components, allergenic products, human cells and tissues, and cell and gene therapies, reviewed across three product offices: Vaccines Research and Review, Blood Research and Review, and Therapeutic Products. CBER does not cover the therapeutic biologics FDA transferred to CDER, including monoclonal antibodies and therapeutic proteins, even though those remain section 351 licenses reviewed under the same statute.

CBER is applied in practice as a routing decision made early. Sponsors confirm center jurisdiction before the pre-IND meeting, because a biologic-device combination goes to whichever center owns the primary mode of action, and a cell or tissue product may sit outside licensing entirely. CBER's Office of Therapeutic Products, the reorganized former Office of Tissues and Advanced Therapies, handles most advanced-therapy programs.

Not to be confused with

CDER
CDER reviews therapeutic biologics such as monoclonal antibodies and therapeutic proteins under the same section 351 licensing pathway. The split between the two centers is by product category, not by statute, and either Director can issue the license.
CDRH
CDRH takes the lead when the device component supplies the primary mode of action. CBER leads only when the biological component provides the most important therapeutic action, which is a determination about mechanism, not about which component is larger or costlier.
Section 361 HCT/Ps
tissue products meeting all the 21 CFR 1271.10 criteria are regulated solely under section 361, with registration and listing but no biologics license. CBER still oversees them; the difference is that no BLA exists to review.
BLA
the BLA is the application document; CBER is one of the two centers that can act on it. Saying "we filed with CBER" describes the review path, not the submission type.

The obligations below are the ones that actually change a sponsor's plan of record.

What you must do

  1. 1Submit the biologics license application to the Director, CBER, supported by nonclinical and clinical data demonstrating safety, purity, and potency21 CFR 601.2(a)
  2. 2Treat the license as valid until suspended or revoked, and keep both the establishment and the product in a state that meets applicable requirements after approval, not just at approval21 CFR 601.4(a)
  3. 3Determine the primary mode of action for any biologic-device or biologic-drug combination before assuming CBER has premarket jurisdiction21 CFR 3.4
  4. 4Test a human cell or tissue product against every criterion in the section 361 list, including minimal manipulation and homologous use, before concluding that no license is required21 CFR 1271.10
  5. 5Register the establishment and submit a list of every HCT/P it manufactures within 5 days after beginning operations21 CFR 1271.21

Common mistakes

  • Assuming "biologic" means CBER

    Monoclonal antibodies and therapeutic proteins were moved to CDER, so a sponsor who builds a CBER-facing regulatory strategy for an antibody is preparing meetings, briefing books, and review-clock assumptions against the wrong center, then discovers it at the pre-IND request.

  • Treating the section 361 pathway as a shortcut

    The 21 CFR 1271.10 criteria are conjunctive. Missing one, most often homologous use, moves the product into full licensing, which means an IND, a BLA, and years of work that the 361-only plan never budgeted.

  • Deferring combination-product jurisdiction to the first review division that answers

    Jurisdiction follows the primary mode of action, not the division you happen to contact. Building a submission for the wrong center means rebuilt modules, a re-scoped quality section, and a review that restarts rather than transfers.

When This Matters

  • Confirm with CBER before the pre-IND meeting, because if the device is the primary mode of action this program belongs to CDRH.
  • The BLA goes to CBER, so the license decision comes from the Director of CBER and not from CDER.
  • We assumed CBER because it is a biologic, and lost six weeks finding out the antibody sits with CDER.

Frequently Asked Questions

CBER regulates vaccines, blood and blood components, allergenic products, human tissues and cellular products, and cell and gene therapies. Its licensing authority runs through section 351 of the Public Health Service Act. Therapeutic proteins and monoclonal antibodies were transferred to CDER, so those sponsors file with CDER even though the products are biologics.

Related Use Cases

Related Regulatory Intelligence

Related Actions

Sources & References

Share this page
Agent CTA Background

Simplify Center for Biologics Evaluation and Research compliance

Book a Demo